These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9237782)

  • 1. The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?
    Ito T; Nishimura C; Takahashi Y; Saito T; Omori Y
    Diabetes Res Clin Pract; 1997 Jun; 36(3):161-7. PubMed ID: 9237782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
    Takahashi Y; Tachikawa T; Ito T; Takayama S; Omori Y; Iwamoto Y
    Diabetes Res Clin Pract; 1998 Nov; 42(2):101-7. PubMed ID: 9886746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
    Nishimura C; Hotta Y; Gui T; Seko A; Fujimaki T; Ishikawa T; Hayakawa M; Kanai A; Saito T
    Diabetes Res Clin Pract; 1997 Sep; 37(3):173-7. PubMed ID: 9306038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
    Nishimura C; Saito T; Ito T; Omori Y; Tanimoto T
    Diabetologia; 1994 Mar; 37(3):328-30. PubMed ID: 8174849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
    Oishi N; Kubo E; Takamura Y; Maekawa K; Tanimoto T; Akagi Y
    Br J Ophthalmol; 2002 Dec; 86(12):1363-6. PubMed ID: 12446366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
    Gupta P; Verma N; Bhattacharya S; Mahdi AA; Usman K; Tiwari S; Bhardwaj K
    Can J Diabetes; 2014 Feb; 38(1):22-5. PubMed ID: 24485209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of interindividual variability of aldose reductase protein content on polyol-pathway metabolites and redox state in erythrocytes in diabetic patients.
    Hamada Y; Nishimura C; Koh N; Sakakibara F; Nakamura J; Tanimoto T; Hotta N
    Diabetes Care; 1998 Jun; 21(6):1014-8. PubMed ID: 9614624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(2):111-5. PubMed ID: 1611134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy.
    Hasegawa G; Obayashi H; Kitamura A; Hashimoto M; Shigeta H; Nakamura N; Kondo M; Nishimura CY
    Diabetes Res Clin Pract; 1999 Aug; 45(1):9-14. PubMed ID: 10499880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
    Hamada Y; Kitoh R; Raskin P
    Diabet Med; 1993; 10(1):33-8. PubMed ID: 8435985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients.
    Hamada Y; Kitoh R; Raskin P
    Diabetes; 1991 Oct; 40(10):1233-40. PubMed ID: 1936586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
    Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
    Reddy GB; Satyanarayana A; Balakrishna N; Ayyagari R; Padma M; Viswanath K; Petrash JM
    Mol Vis; 2008 Mar; 14():593-601. PubMed ID: 18385795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860).
    Asano T; Saito Y; Kawakami M; Yamada N; Sekino H; Hasegawa S;
    J Diabetes Complications; 2004; 18(6):336-42. PubMed ID: 15531183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study.
    Franklin GM; Shetterly SM; Cohen JA; Baxter J; Hamman RF
    Diabetes Care; 1994 Oct; 17(10):1172-7. PubMed ID: 7821138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
    Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
    Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
    Dent MT; Veves A; Tebbs SE; Gonzalez AM; Malik RA; Boulton AJ; Ward JD; Wilson RM
    Diabet Med; 1991 Dec; 8(10):911-6. PubMed ID: 1838041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.